<p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">To address the risk of thrombosis in patients with COVID-19, many academic groups in China and abroad have issued relevant guidelines for the prevention and treatment of thrombosis in COVID-19 patients. Most guidelines refer to anticoagulant therapy with heparin or low-molecular-weight heparin, but only a few guidelines mention direct oral anticoagulant (rivaroxaban) (<xref rid="B122" ref-type="bibr">122</xref>, <xref rid="B123" ref-type="bibr">123</xref>).</p>